

11-2-04

11-05-2004

FORM PTO-1595 (modified)

RECO




U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

102875630

To the Honorable Assistant Secretary and Commissioner of Patents and Trademarks: Please record the attached original document thereof.

1. Name of conveying party(ies):  
TAKEDA CHEMICAL INDUSTRIES, LTD.  
Additional name(s) of conveying party(ies) attached? NO



2. Name and address of receiving party(ies):  
Name: TAKEDA PHARMACEUTICAL COMPANY LIMITED  
Street Address: 1-1 Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 540-8645, Japan

3. Nature of conveyance:  
 Assignment  Merger  
 Security Agreement  **Change of Name**  
 Other \_\_\_\_\_  
Execution Date: June 29, 2004

Additional name(s) & address(es) attached? NO

4. Application number(s) or patent number(s):  
If this document is being filed together with a new application, the execution date of the application is:  
A. Patent Application No.(s)  
10/381,002, filed March 20, 2003

B. Patent No.(s)

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:  
Name: WENDEROTH, LIND & PONACK, L.L.P.  
Attn: Warren M. Cheek, Jr., Esq.  
Street Address: 2033 K Street, N.W., Suite 800  
City: Washington, State: DC ZIP: 20006-1021

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41). . . . . \$ 40.00  
 Enclosed (Check No. 64912)  
Authorized to be charged to deposit account

8. Deposit account number: 23-0975  
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.  
*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

Warren M. Cheek, Jr., Reg. No. 33,367  
Name of Person Signing

Warren M. Cheek, Jr.  
Signature

November 2, 2004  
Date

JAPANESE VERSION AND ENGLISH TRANSLATION ENCLOSED

Total number of pages including cover sheet: 6

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information:

Commissioner and Assistant Secretary of Patents and Trademarks  
Box Assignments  
Washington, D.C. 20231

11/04/2004 INETACHE 00000275 10381002

01 FC:8021

40.00 DP

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding the burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

*TRANSLATION: Please note that the following is an English translation of the original Japanese version, prepared only for the convenience of shareholders residing outside Japan. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.*

June 29, 2004

**To Our Shareholders**

Yasuchika Hasegawa  
President and Representative Director  
Takeda Pharmaceutical Company Limited  
1-1 Doshomachi 4-chome  
Chuo-ku, Osaka 540-8645,  
Japan

**Notice of Resolutions at the 128th Ordinary General Meeting of Shareholders**

Dear Shareholders:

The following matters were reported and resolved at the 128th Ordinary General Meeting of Shareholders of the Company held today.

**Items reported on:**

Business Report, Balance Sheet and Statement of Income for the 127th term (from April 1, 2003 to March 31, 2004)

The contents of these financial documents were reported.

**Items resolved:**

**First Proposal:** Approval of Proposed Appropriation of Retained Earnings for the 127th term

This item was approved as originally proposed. (The dividend is 41 yen per share.)

**Second Proposal:** Partial Amendment of the Articles of Incorporation

This item was approved as originally proposed. (Details of the amendment are described on page 2 .)

**Third Proposal:** Election of three (3) Directors

As proposed, three directors – Messrs. Hiroshi Akimoto, Makoto Yamaoka and Kiyoshi Kitazawa – were re-elected and assumed their respective offices.

**Fourth Proposal:** Election of two (2) Corporate Auditors

As proposed, Mr. Kiyoshi Taura was re-elected, Mr. Yoichi Asakawa was newly elected, and each assumed his respective office.

Both individuals are Outside Corporate Auditors as provided in Section 1, Article 18 of the "Commercial Code Special Measures Law Concerning Audit, etc. of *Kabushiki Kaisha* (Corporations)."

**Fifth Proposal:** Payment of retirement benefits to a retired Corporate Auditor

It was proposed and approved that retirement benefits be paid to the retired Corporate Auditor Mr. Kunio Ueshima within a reasonable amount based on the specified standards of the Company, and the Corporate Auditors were authorized to determine the exact amount, the date of the payment and the payment manner.

Details of Amendment to Articles of Incorporation (underlines indicate changes)

Before Amendment	After Amendment
Article 1. (Corporate Name) The Company shall be named Takeda Yakuhin Kogyo Kabushiki Kaisha, displayed in English as <u>Takeda Chemical Industries, Ltd.</u>	Article 1. (Corporate Name) The Company shall be named Takeda Yakuhin Kogyo Kabushiki Kaisha, displayed in English as <u>Takeda Pharmaceutical Company Limited.</u>
(New)	<u>Article 6. (Acquisition of the Company's Own Shares)</u> <u>The Company may, by resolution of the Board of Directors, acquire its own shares as provided in Article 211-3, Section 1, Sub-section 2 of the Commercial Code.</u>
Article <u>6</u> – Article <u>31</u> (Text of articles omitted)	Article <u>7</u> – Article <u>32</u> (Same as present)



平成16年6月29日

# 株主各位

大阪府中央区道修町四丁目1番1号  
武田薬品工業株式会社  
代表取締役社長 長谷川 閑史

## 第128回定時株主総会決議ご通知

拝啓 ますますご清栄のこととお喜び申しあげます。  
さて、本日開催の当社第128回定時株主総会において、下記のとおり報告ならびに決議されましたので、ご報告申しあげます。

敬 具

### 記

報告事項 第127期（平成15年4月1日から）  
（平成16年3月31日まで）  
営業報告書、貸借対照表および損益計算書報告の件  
本件は、上記計算書類の内容を報告いたしました。

### 決議事項

第1号議案 第127期利益処分案承認の件  
本件は、原案どおり承認可決されました。  
（利益配当金 1株につき41円）

第2号議案 定款一部変更の件  
本件は、原案どおり承認可決されました。  
（変更内容は3頁に記載のとおりであります。）

### 第3号議案 取締役3名選任の件

本件は、秋元 浩、山岡 眞、北澤 清の3名が再選され、それぞれ就任いたしました。

### 第4号議案 監査役2名選任の件

本件は、田浦 清が再選され、浅川洋一が新たに選任され、それぞれ就任いたしました。なお、両名は「株式会社の監査等に関する商法の特例に関する法律」第18条第1項に定める社外監査役であります。

### 第5号議案 退任監査役に対し退職慰労金贈呈の件

本件は、退任監査役 上島邦夫氏に対し、当社における一定の基準に従い相当額の範囲内で退職慰労金を贈呈することとし、その具体的金額は、贈呈の時期、方法等とともに、監査役の協議に一任することに承認可決されました。

以上

---

### 配当金のお支払いについて

第127期利益配当金は、同封の「郵便振替支払通知書」により、お近くの郵便局で払渡し期間中にお受け取りください。

なお、配当金振込先をご指定の方には、「利益配当金計算書」および「配当金振込先のご確認について」を同封いたしておりますのでご確認ください。

定款変更の内容

(下線は変更部分)

変 更 前	変 更 後
<p>第1条(商号)                      当社は、武田薬品工業株式会社と称し、英文では<u>Takeda Chemical Industries, Ltd.</u>と表示する。</p> <p>(新 設)</p> <p>第6条～第31条                      (条文の記載省略)</p>	<p>第1条(商号)                      当社は、武田薬品工業株式会社と称し、英文では<u>Takeda Pharmaceutical Company Limited</u>と表示する。</p> <p>第6条(自己株式の取得)                      当社は、<u>商法第211条の3第1項第2号の規定により、取締役会の決議をもって自己株式を買受けることができる。</u></p> <p>第7条～第32条                      (現行どおり)</p>